Shin Poong Pharmaceutical Co. Ltd. and Medicines for Malaria Venture are pleased to launch Pyramax!
Wednesday, 20 April 2016
Pyramax (pyronaridine-artesunate), a once-daily, 3-day artemisinin combination therapy (ACT) for uncomplicated malaria, has received a positive scientific opinion under Article 58 from the European Medicine’s Agency (EMA) for a new label allowing it to be used to treat malaria without geographic restrictions or limitations on its repeat dosing. Read the news story.
Pyramax® Granules, the child-friendly fixed-dose ACT of pyronaridine and artesunate, is the first paediatric antimalarial to be granted a positive scientific opinion from the European Medicines Agency (EMA) under Article 58. Read the news story.
This technical briefing will address the clinical evidence that forms the basis of this positive scientific opinion, the implementation strategy to provide rapid access to this drug in malaria-endemic countries, and the vital role of Pyramax in malaria control, elimination and eradication.
Club Suisse de la Presse,
106 Route de Ferney, Geneva
- Prof. Abdoulaye Djimdé, University of Science Techniques and Technologies of Bamako: Real-world safety and efficacy of Pyramax – The WANECAM study
- Dr Michael Ramharter, Medical University of Vienna: What’s next for Pyramax?
MMV's David Reddy will be speaking at this event with Mr Won June, Shin Poong : Welcome and introduction – Partnering to develop Pyramax
MMV's Isabelle Borghini-Fuhrer will be speaking at this event :The development of Pyramax – A highly effective antimalarial for all age groups
MMV's Stephan Duparc will be speaking at this event: Pyramax Granules – Providing treatment options for children